PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage regenerative medicine company focused on developing cell-based therapies for chronic kidney disease, most notably its renal autologous cell therapy platform. The company became publicly traded following a business combination with SCS Capital Acquisition Corp. (SCSA), a blank-check company sponsored by SCS Capital Management that completed its SPAC IPO in 2021, with the de-SPAC merger closing in January 2023. ProKidney operates in the biotechnology and cell therapy sector, and in April 2026 filed a DEF 14A definitive proxy statement with the SEC, putting matters before shareholders for a formal vote. Visit SpacDesk to access the full deal timeline, filing history, and analytics for PROK and thousands of other SPAC transactions.